Skip to main content
placeholder image

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2015

Citation


  • Basch, E. M., Scholz, M. C., De Bono, J. S., Vogelzang, N. J., De Souza, P. L., Marx, G. M., . . . Scher, H. I. (2015). Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 33(7_suppl), 141. doi:10.1200/jco.2015.33.7_suppl.141

Web Of Science Accession Number


Start Page


  • 141

End Page


  • 141

Volume


  • 33

Issue


  • 7_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2015

Citation


  • Basch, E. M., Scholz, M. C., De Bono, J. S., Vogelzang, N. J., De Souza, P. L., Marx, G. M., . . . Scher, H. I. (2015). Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 33(7_suppl), 141. doi:10.1200/jco.2015.33.7_suppl.141

Web Of Science Accession Number


Start Page


  • 141

End Page


  • 141

Volume


  • 33

Issue


  • 7_suppl

Place Of Publication